Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye movements may reveal who benefits from depression medication

NCT ID NCT07723079

Ongoing Symptom relief Sponsor: University of Sao Paulo Source: ClinicalTrials.gov ↗

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This study tests whether eye-tracking can predict if the drug brexpiprazole will improve symptoms in adults with major depressive disorder. One participant will take brexpiprazole or placebo while researchers measure their visual attention to emotional images. The goal is to see if changes in eye patterns early in treatment can forecast clinical response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
brexpiprazole as an add-on treatment
What this could lead to
If eye-tracking can predict who will respond to brexpiprazole, it could become a low-cost tool to guide depression treatment decisions.
What could go wrong
This is a single-person study, so results may not apply to others. The approach is still experimental and needs much larger trials to confirm.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEPRESSION - MAJOR DEPRESSIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DEPRESSION - MAJOR DEPRESSIVE DISORDER

Contacts and locations

Locations

  • Hospital das Clínicas da faculdade de medicina da Universidade de São Paulo

    São Paulo, São Paulo, 05403-000, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.